Brazil says Sputnik's vaccine approval in other countries not enough
Gustavo Mendes, a drug manager at Anvisa, said the agency had not received enough data to approve the Sputnik V vaccine
The calculations were based on preliminary data obtained 42 days after the first dose, Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement. Photo: Reuters
A Brazilian health regulator official told a congressional hearing on Tuesday that the approval of Russia's Sputnik V vaccine by other countries does not mean it meets Brazilian regulatory requirements.
Gustavo Mendes, a drug manager at Anvisa, said the agency had not received enough data to approve the Sputnik V vaccine.
Keep updated, follow The Business Standard's Google news channel
